Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus.

Background: Currently, there is no antiviral licensed to treat chikungunya fever, a disease caused by the infection with Alphavirus chikungunya (CHIKV). Treatment is based on analgesic and anti-inflammatory drugs to relieve symptoms. Our study aimed to evaluate the antiviral activity of sulfadoxine (SFX), an FDA-approved drug, and its derivatives complexed with silver(I) (AgSFX), salicylaldehyde Schiff base (SFX-SL), and with both Ag and SL (AgSFX-SL) against CHIKV.

Single-molecule magnet behaviour and catalytic properties of tetrahedral Co(II) complexes bearing chloride and 1,2-disubstituted benzimidazole as ligands.

Five cobalt(II) complexes of formula [CoCl(L)] [1 with L1 = 1-benzyl-2-phenyl-1-benzimidazole, 2 with L2 = 2-(furan-2-yl)-1-(furan-2-ylmethyl)-1-benzimidazole, 3 with L3 = 1-(4-chlorobenzyl)-2-(4-chlorophenyl)-1-benzimidazole, 4 with L4 = 1-(2-methoxybenzyl)-2-(2-methoxyphenyl)-1-benzimidazole and 5 with L5 = 2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1-benzimidazole] have been synthesised, spectroscopically characterised and cryomagnetically investigated. The crystal structures of 1, 3, 4 and 5 have been determined by X-ray diffraction on single crystals. Each cobalt(II) ion is four-coordinate in a distorted tetrahedral environment built by two chloride anions and two benzimidazole ligands.